Glycan-masked engineered outer domains of HIV-1 gp120 and their use
US12053520B2 · kind B2 · utility
0Cited by
2References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 2022 |
| Grant date | Aug 6, 2024 |
| Priority date | — |
| Expiry date | Apr 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments of immunogens based on the outer domain of HIV-1 gp120 and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to prime an immune response to gp120 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.